[1]王 杰,骆寅峰.辛伐他汀联合美多巴治疗老年患者帕金森病伴动脉粥样硬化的疗效观察[J].医学信息,2023,36(02):134-137.[doi:10.3969/j.issn.1006-1959.2023.02.028]
　WANG Jie,LUO Yin-feng.Efficacy Observation of Simvastatin Combined with Madopar in the Treatment of Parkinson’s Disease with Atherosclerosis in Elderly Patients[J].Journal of Medical Information,2023,36(02):134-137.[doi:10.3969/j.issn.1006-1959.2023.02.028]
点击复制

辛伐他汀联合美多巴治疗老年患者帕金森病伴动脉粥样硬化的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年02期
页码:
134-137
栏目:
药物与临床
出版日期:
2023-01-15

文章信息/Info

Title:
Efficacy Observation of Simvastatin Combined with Madopar in the Treatment of Parkinson’s Disease with Atherosclerosis in Elderly Patients
文章编号:
1006-1959（2023）02-0134-04
作者:
王 杰; 骆寅峰
（佳木斯市中心医院康复科，黑龙江 佳木斯 154002）
Author(s):
WANG Jie; LUO Yin-feng
(Department of Rehabilitation,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
辛伐他汀; 美多巴; 老年帕金森; 动脉粥样硬化
Keywords:
Simvastatin; Madopar; Elderly Parkinson’s disease; Atherosclerosis
分类号:
R742.5；R543.5
DOI:
10.3969/j.issn.1006-1959.2023.02.028
文献标志码:
A
摘要:
目的 观察辛伐他汀联合美多巴治疗老年患者帕金森病伴动脉粥样硬化的疗效。方法 选取2020年1月-2021年8月在我院诊治的52例老年帕金森病伴动脉粥样硬化患者为研究对象，采用随机数字表法分为对照组和观察组，各26例。对照组采用美多巴治疗，观察组在对照组基础上联合辛伐他汀治疗。比较两组临床治疗总有效率、改良Webster PD功能障碍评分、日常生活能力评分、神经临床症状评分、血清Cys-C、Hcy水平以及临床不良反应发生情况。结果 观察组治疗总有效率为92.31%，高于对照组的80.77%（P＜0.05）；两组Webster PD评分均低于治疗前，日常生活能力各维度评分均高于治疗前，且观察组Webster PD评分低于对照组，日常生活能力各维度评分高于对照组（P＜0.05）；观察组口干、出汗、尿频尿急、便秘、流涎评分均低于对照组（P＜0.05）；观察组Cys-C、Hcy水平均低于治疗前，且观察组低于对照组（P＜0.05），对照组与治疗前比较，差异无统计学意义（P＞0.05）；观察组不良反应发生率为7.69%，低于对照组的19.23%（P＜0.05）。结论 辛伐他汀联合美多巴治疗老年患者帕金森病伴动脉粥样硬化效果明确，且可改善患者动脉粥样硬化，促进患者神经症状改善，提高患者日常生活能力，且可降低不良反应发生率，是一种有效、安全的治疗方案。
Abstract:
Objective To observe the efficacy of simvastatin combined with madopar in the treatment of Parkinson’s disease with atherosclerosis in elderly patients.Methods A total of 52 elderly patients with Parkinson’s disease and atherosclerosis who were treated in our hospital from January 2020 to August 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 26 cases in each group. The control group was treated with Madopar, and the observation group was treated with simvastatin on the basis of the control group. The total effective rate of clinical treatment, modified Webster PD dysfunction score, daily living ability score, neurological clinical symptom score, serum Cys-C, Hcy level and clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 92.31%, which was higher than 80.77% in the control group (P<0.05). The Webster PD scores of the two groups were lower than those before treatment, and the scores of each dimension of daily living ability were higher than those before treatment, while the Webster PD score of the observation group was lower than that of the control group, and the scores of each dimension of daily living ability were higher than those of the control group (P<0.05). The scores of dry mouth, sweating, frequent urination, urgency, constipation and salivation in the observation group were lower than those in the control group (P<0.05). The levels of Cys-C and Hcy in the observation group were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). There was no significant difference between the control group and before treatment (P>0.05). The incidence of adverse reactions in the observation group was 7.69%, which was lower than 19.23% in the control group (P<0.05).Conclusion Simvastatin combined with madopar is effective in the treatment of Parkinson’s disease with atherosclerosis in elderly patients, which can improve atherosclerosis, promote the improvement of neurological symptoms, improve the daily living ability of patients, and reduce the incidence of adverse reactions. It is an effective and safe treatment.

参考文献/References:

[1]中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.[2]Jiang Z,Xu X,Gu X,et al.Effects of Higher Serum Lipid Levels on the Ｒisk of Parkinson＇s Disease: A Systematic Review and Meta-Analysis[J].Front Neurol,2020,11:597.[3]张磊.辛伐他汀联合美多巴治疗老年患者帕金森病伴动脉粥样硬化的疗效观察[J].吉林医学,2020,41(7):1580-1583.[4]刘贵安,时晶.帕金森病患者血清25-羟维生素DHcy水平与认知功能障碍的关系[J].河北医学,2019,25(2):201-205.[5]刘琰,李光宇,王晓旭,等.帕金森病患者脑深部电刺激术后的非运动症状及其对生活质量的影响[J].中国医科大学学报,2020,49(1):43-47.[6]方娟,马慧娟,胡盼盼,等.多巴胺能药物对早期帕金森病患者模糊决策功能的影响[J].中华行为医学与脑科学杂志,2016,25(12):1091-1095.[7]杨改清,李晓昶,张晓艺,等.不同亚型帕金森病患者认知功能障碍的临床观察[J].中国实用神经疾病杂志,2018,21(1):51-54.[8]Wang YX,Zhao J,Li DK,et al.Associations between cognitive impairment and motor dysfunction in Parkinson’s disease[J].Brain Behav,2017,7(6):e00719.[9]白莹莹,张红菊,李中林,等.伴快速眼动睡眠期行为障碍的帕金森患者认知与脑功能连接研究[J].中国神经精神疾病杂志,2019,45(1):1-6.[10]Kumar P,Sharma R,Misra S,et al.CIMT as a risk factor for Stroke Subtype: A Systematic Review[J].Eur J Clin Invest,2020,50(11):e13348.[11]张兰.盐酸普拉克索联合多巴丝肼对帕金森氏病的临床效果[J].包头医学院学报,2017,33(9):74-75.[12]闫维维,李林忆,马建军,等.脑血管危险因素对帕金森病患者颈动脉斑块的影响[J].中国实用神经疾病杂志,2019,22(7):702-708.[13]李小盼,张艳,高冰心,等.原发性帕金森病患者颈部动脉粥样硬化情况及分析[J].医药论坛杂志,2021,42(1):23-25.[14]蒋德旗,徐兰程,毛书慧,等.SIRT3介导褪黑激素保护帕金森病多巴胺能神经元的作用机制[J].中国药理学通报,2020,36(1):121-126.[15]余伟雄.盐酸多奈哌齐治疗帕金森伴发轻度认知障碍的效果[J].中国医药科学,2019,5(2):90-92.[16]Yan LY,He QF,Lu MY,et al.Association between carotid plaque and Parkinson’s disease[J].Ann Transl Med,2019,7(5): 94.[17]张洪波,陈冬霞,冯青芝,等.胞磷胆碱钠联合多奈哌齐治疗帕金森病合并认知障碍患者的效果[J].河南医学研究,2021,28(5):48-50.[18]程海涛,胡文辉.急性脑梗死患者颈动脉粥样硬化斑块与血hs-CRP、FIB及HCY的关系[J].内科急危重症杂志,2018,24(4):306-308.

相似文献/References:

[1]何 丽.三种他汀类药物治疗老年动脉粥样硬化性急性脑梗死合并高血脂效果对比[J].医学信息,2022,35(11):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
　HE Li.Comparison of Three Statins in the Treatment of Elderly Patients with Atherosclerotic Acute Cerebral Infarction Combined with Hyperlipidemia[J].Journal of Medical Information,2022,35(02):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
[2]张素云,耿继光.阿托伐他汀钙联合硝苯地平、盐酸普萘洛尔治疗 冠心病的临床效果[J].医学信息,2019,32(17):139.[doi:10.3969/j.issn.1006-1959.2019.17.046]
　ZHANG Su-yun,GENG Ji-guang.Clinical Effect of Atorvastatin Calcium Combined with Nifedipine and Propranolol Hydrochloride in the Treatment of Coronary Heart Disease[J].Journal of Medical Information,2019,32(02):139.[doi:10.3969/j.issn.1006-1959.2019.17.046]
[3]李 鹏,李爱歆.美多巴联合普拉克索治疗帕金森病的有效性及安全性[J].医学信息,2020,33(09):146.[doi:10.3969/j.issn.1006-1959.2020.09.048]
　LI Peng,LI Ai-xin.The Efficacy and Safety of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Disease[J].Journal of Medical Information,2020,33(02):146.[doi:10.3969/j.issn.1006-1959.2020.09.048]

更新日期/Last Update: 1900-01-01